Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11 studies found for:    17021319 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
Condition: Neovascular Age-related Macular Degeneration
Interventions: Procedure: 1+PRN;   Procedure: 3+PRN;   Drug: Ranibizumab
2 Recruiting Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: ranibizumab
3 Recruiting Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
Condition: Radiation Retinopathy
Interventions: Drug: 0.5 mg ranibizumab;   Procedure: Targeted Retinal Photocoagulation
4 Completed
Has Results
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Conditions: Exudative Age-related Macular Degeneration;   Polypoidal Choroidal Vasculopathy
Intervention: Drug: aflibercept
5 Recruiting Proton Radiation Therapy for Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Radiation: Proton radiation
6 Completed
Has Results
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: ranibizumab
7 Active, not recruiting Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Condition: Macular Degeneration
Intervention: Drug: 0.5mg ranibizumab
8 Completed Study for Recalcitrant Age Related Macular Degeneration
Condition: Age Related Macular Degeneration
Intervention: Drug: aflibercept 2.0 mg
9 Unknown  Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Conditions: Macular Degeneration;   Visual Acuity
Intervention: Drug: Ranibizumab
10 Terminated
Has Results
Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Interventions: Drug: Ranibizumab (Lucentis);   Drug: 0.5mg ranibizumab
11 Completed A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)

Indicates status has not been verified in more than two years